All In Biotech

Drug Trial Radar · NCT05742607

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-Stage (II to III) Non-Small Cell Lung CancEr (MATISSE)

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jun 23, 2023

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Innate PharmaIndustry
Sponsor type
Industry
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC). Study Design was updated following the results of interim analysis # 2 (protocol amendment, adding cohort 2). Cohort 2 includes patients with resectable Stage II to IIIB NSCLC expressing PD-L1 ≥1%, receiving (only) neoadjuvant IPH5201+ durvalumab + chemotherapy

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • IPH5201 + durvalumab + standard chemotherapyDrug

    Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pCR)Time frame: 16 weeks after the first dose of study intervention.
  2. Adverse events (AEs) and serious adverse events (SAEs)Time frame: Until Day 90 after the last dose of study interventions.

Locations

30 sites in 5 countries. Site status is shown where the registry gives one.

  • St. Anthony's Hospital - BayCare Health System

    St. Petersburg, Florida · Terminated

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida · Terminated

  • University of Chicago Medical Center

    Chicago, Illinois · Withdrawn

  • Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics

    Lake Success, New York · Withdrawn

  • Millennium Research & Clinical Development

    Houston, Texas · Terminated

  • UW Carbone Cancer Center - Cancer Connect

    Madison, Wisconsin · Terminated

  • Angers University Hospital Center

    Angers, France · Terminated

  • University Hospital Center Caen

    Caen, France · Terminated

  • Hospital Calmette

    Lille, France · Not yet recruiting

  • CHU de Limoges

    Limoges, France · Recruiting

  • Leon Berard Center

    Lyon, France · Recruiting

  • Marseille University Hospital Center - North Hospital

    Marseille, France · Recruiting

  • Rennes University Hospital Center - Hospital Pontchaillou

    Rennes, France · Recruiting

  • Charles Nicolle Hospital

    Rouen, France · Terminated

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Henry Dunant Hospital Center

    Athens, Greece · Withdrawn

  • University General Hospital "Attikon"

    Athens, Greece · Recruiting

  • University General Hospital of Ioannina

    Ioannina, Greece · Terminated

  • University General Hospital of Patras

    Pátrai, Greece · Terminated

  • Koranyi National Institute of Pulmonology, 14th Department of Pulmonology

    Budapest, Hungary · Recruiting

  • Veszprem County Pulmonology Institute

    Farkasgyepű, Hungary · Terminated

  • Petz Aladar University Teaching Hospital, Department of Pulmonology

    Győr, Hungary · Terminated

  • Jasz-Nagykun-Szolnok County Hetenyi Geza Hospital-Clinic, Department of Oncology

    Szolnok, Hungary · Recruiting

  • Pulmonology Institute Torokbalint

    Törökbálint, Hungary · Not yet recruiting

  • University Teaching Hospital in Bialystok, 2nd Department of Lung Diseases and Tuberculosis

    Bialystok, Poland · Recruiting

  • John Paul II Specialist Hospital in Krakow

    Krąków, Poland · Terminated

  • Mandziuk Slawomir - Specialist Medical Practice

    Lublin, Poland · Terminated

  • Eugenia and Janusz Zeyland Wielkopolskie Centre of Pulmonology and Thoracic Surgery

    Poznan, Poland · Terminated

  • Specialist Hospital in Prabuty Sp. z o.o. (LLC)

    Prabuty, Poland · Recruiting

  • Military Institute of Medicine - National Research Institute

    Warsaw, Poland · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.